12:00 AM
Feb 13, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

CMX001: Phase II data

The double-blind, dose-escalation, U.S. Phase II Study 201 trial in 230 allogeneic HSCT recipients showed that twice-weekly 100 mg CMX001 met the primary endpoint of significantly reducing the proportion of patients with CMV viremia >200 copies/mL or with CMV disease at 13 weeks post-transplant vs. placebo (10% vs. 37%, p=0.001). The once-weekly 40, 100 and 200 mg and twice-weekly 200 mg doses of CMX001 missed the endpoint (52%, 22%, 31% and 23%, respectively; p=0.34, p=0.19, p=0.31 and p=0.09). Additionally, the once-weekly 200 mg and twice-weekly 100 and 200 mg doses of CMX001 significantly reduced the proportion of patients with CMV viremia >=1,000...

Read the full 487 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >